Neldaleucel
Cell therapy
Also known as MT-601
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
APOLLO NCT05798897 · Relapsed/Refractory Non-Hodgkin Lymphoma Registry: NCT05798897 | 1 | Dose Escalation (After 3 or 6 patients in each dose cohort have been treated with MT-601 and have had the opportunity to be followed for 28 days.); Dose Expansion (ORR) (12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.); Dose Expansion (DOR) (12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.); Dose Expansion (CR) (12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.) 2028-02-28 | In progress: results expected 28 Feb 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Relapsed/Refractory Non-Hodgkin Lymphoma: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Neldaleucel: this drug | Phase 1 | Cell therapy | Six tumor-associated antigens | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Neldaleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.